National Institutes of Health, National Heart, Lung, and Blood Institute, Contracts Operations Branch, 6701 Rockledge Drive, Room 6100, MSC 7902, Bethesda, MD 20892

B -- SPECIAL STUDIES AND ANALYSIS -- NOT R&D SOL NHLBI-PS-99-505 DUE 092899 POC Deborah Coulter, Purchasing Agent, (301) 435-0368 Fax (301) 480-3345 The National Heart, Lung, and Blood Institute intends to negotiate on a sole source basis with Genome Systems, Inc., 4633 World Parkway Circle, St. Louis, MO, 63134, to provide the Gene Analysis services as outlined in the Statement of Work. The Genome Systems Division of Incyte Pharmaceuticals will perform custom gene expression analysis utilizing their human UniGEM V gene probes. This custom gene expression analysis service is required for the analysis of gene expression in human lung cells from patients with pulmonary disease, such as lymphangioleiomyomatosis, asthma, sarcoidosis and pulmonary fibrosis. The use of this service will allow the identification of differentially expressed genes in lung cell populations from patients with lung disease. Total RNA from patient lung cells will be isolated and sent to the Genome Systems Division of Incyte Pharmaceuticals. All subsequent sample processing will be performed by the Genome Systems Division of Incyte Pharmaceuticals. This will involve the isolation of poly A mRNA, which will then be labeled and hybridized to their probes on glass slides. The Genome Systems Division of Incyte Pharmaceuticals will then provide the data generated from comparative ratio analysis to us which can then be analyzed utilizing their gene group functional hierarchical analysis software which we are purchasing. The Genome Systems Division of Incyte Pharmaceuticals will perform 50 poly AmRNA isolations and 25 GEM hybridizations. The data from these 25 GEMs will then be sent to the P-CCMB for further analysis utilizing the GEM Tools Software Analysis software which we are purchasing. The RNA samples are to be received by the Genome Systems Division of Incyte Pharmaceuticals by September 30, 1999. No government data, property or facilities will be provided to the vendor. The Genome Systems Division of Incyte Pharmaceuticals will provide the data generated from comparative ratio analysis for each GEM 15 to 20 working days from receipt of the RNA. No program management or control requirements exist regarding this purchase. The data generated from this custom gene expression analysis software will be received, inspected and accepted by Pulmonary- Critical Care Medicine Branch Senior Investigators. This acquisition is being conducted under simplified acquisition procedures and is exempt from the requirements of FAR Part 6. The Standard Industrial Classification (SIC) Code 8734, Size Standard is $5.0M. The Small Business Set-Aside has been lifted for this requirement. This notice of intent is not a request for competitive proposals. Interested parties may identify their interest and capabilities in response to this requirement. The determination by the Government not compete the proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct future competitive procurement. Responses to this announcement, referencing synopsis number NHLBI-PS-99-505may be submitted to the National Heart, Lung and Blood Institute, Contracts Operations Branch Procurement Section, Building RKL2, Room 6151, 6701 Rockledge Drive, Bethesda, MD 20892-7902, Attention Deborah Coulter, Purchasing Agent. All responsible sources may submit a quotation, which if timely received, shall be considered by the agency. Posted 09/14/99 (W-SN379911). (0257)

Loren Data Corp. http://www.ld.com (SYN# 0020 19990916\B-0007.SOL)